Claris Bio Secures $118 Million in Latest Series B Funding Round

Claris Bio secured $118 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Claris Bio Raises $118 million in Funding

Claris Bio raises $118m for eye disease therapy. IMAGE C/O LIFESCI COMMUNICATIONS Claris Biotherapeutics is setting its sights on a breakthrough in ophthalmology.

Investors Behind the Funding

The round was backed by Samsara Biocapital. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Claris Bio operates in Healthcare & Life Sciences. Claris Bio's financing adds to recent private-market activity.

Strategic Use of Funds

Move eye drop into pivotal testing The late-stage biotech has secured funding to advance first potential drug therapy for blinding corneal disease through the clinic.

Looking Ahead

This differed from the A in size and the level of risk,

Source reference: original announcement/article.